Grundinformationen
- Standard-SMILES
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl- InChIKey
BEEDODBODQVSIM-UHFFFAOYSA-N- Summenformel
- C16H24N2O.ClH
- Durchschnittliche Molmasse
- 296,83 g/mol
- Monoisotopische Masse
- 296,1655411
Überblick
Oxymetazoline hydrochloride is a hydrochloride salt resulting from the reaction of equimolar quantities of oxymetazoline and hydrogen chloride. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used to relieve nasal congestion. It has a role as a sympathomimetic agent, an alpha-adrenergic agonist, a vasoconstrictor agent and a nasal decongestant. It contains an oxymetazoline(1+).
Namen und Bezeichner
- Bevorzugter Name
- Oxymetazoline Hydrochloride
- IUPAC
- 6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol;hydrochloride
Namen und Synonyme
Oxymetazoline hydrochloride2315-02-8Oxymetazoline HClOcuclearAfrazineNostrillaRhofadeSch 9384Visine L.R.Vicks SinexAnefrin nasalK89MJ0S5VY
Weitere Namen anzeigen
NSC-757254UPNEEQAgn-199201SCH-9384CHEBI:7863DTXSID801777292-(4-t-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazolinium chloride2,6-Dimethyl-2-(4-tertiarybutyl-3-hydroxyphenyl)methylimidazoline hydrochloride
Datenbank-Bezeichner
- CAS
2315-02-8- PubChem CID
- 66259
- DTXSID
DTXSID80177729- ChEMBL
CHEMBL1200791- ChEBI
CHEBI:7863- UNII
- K89MJ0S5VY
- EC Number
- 219-015-0
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 44,6 Ų
- H-Brücken-Donoren
- 3
- H-Brücken-Akzeptoren
- 2
- Frei drehbare Bindungen
- 3
- Schwere Atome
- 20
- Formalladung
- 0
- Komplexität
- 345
Experimentelle und physikochemische Eigenschaften
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Collision Cross Section169.9 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
Sicherheit und Regulatorisches
GHS-Klassifizierung
GHS Classification
Danger
H300 (75%): Fatal if swallowed [Danger Acute toxicity, oral]
P260, P264, P264+P265, P270, P271, P273, P280, P284, P301+P316, P304+P340, P305+P354+P338, P316, P317, P319, P320, P321, P330, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 148 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Regulatory Information
Chemical: Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-, monohydrochloride
Oxymetazoline hydrochloride: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-, monohydrochloride: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 1 (75%)
Chemie und Industrie
Pharmakologische Informationen
FDA Pharmacological Classification
ALLERGY SINUS
Increased Sympathetic Activity [PE]; Vasoconstriction [PE]; Imidazolines [CS]; Vasoconstrictor [EPC]
NASAL OXYMETAZOLINE HCL
Increased Sympathetic Activity [PE]; Vasoconstriction [PE]; Imidazolines [CS]; Vasoconstrictor [EPC]
OXYMETAZOLINE HCL
Increased Sympathetic Activity [PE]; Imidazolines [CS]; Vasoconstriction [PE]; Vasoconstrictor [EPC]
MeSH Pharmacological Classification
Drugs that selectively bind to and activate alpha adrenergic receptors.
Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.
Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993)
Zugehörige Reaktionen
1
Verknüpfte Notizen
Wird geladen…